blurry vision on semaglutide loss with GLP-1s: Wegovy may have 5 times higher risk What do you think of

According to the FDA announcement, Wegovy is approved to reduce the risk of major cardiovascular events such as stroke, heart attack, and cardiovascular death in adults with overweight or obesity and existing cardiovascular disease

Saudi J Biol Sci (2022) 29(2):8727

Route Subcutaneous injection Schedule Weekly subcutaneous injections with gradual titration Injection Sites Rotate injection sites Dosing Dose Range: 210 mg weekly Use sterile technique when handling and administering Goal: Support significant weight reduction and metabolic improvements Frequency: Once weekly (use same day each week) Storage - Lyophilized: Store at 20 C or below in dry, dark conditions Storage - Reconstituted: Refrigerate at 28 C

Halal certified product